Found: 15
Select item for more details and to access through your institution.
Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer.
- Published in:
- Chemotherapy (0009-3157), 2015, v. 60, n. 3, p. 180, doi. 10.1159/000371870
- By:
- Publication type:
- Article
Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 17, p. 2300, doi. 10.1111/1759-7714.14055
- By:
- Publication type:
- Article
Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 9, p. 1764, doi. 10.1111/1759-7714.13134
- By:
- Publication type:
- Article
Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 3, p. 452, doi. 10.1111/1759-7714.12958
- By:
- Publication type:
- Article
Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 2, p. 341, doi. 10.1111/1759-7714.12952
- By:
- Publication type:
- Article
Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series.
- Published in:
- Thoracic Cancer, 2018, v. 9, n. 10, p. 1305, doi. 10.1111/1759-7714.12844
- By:
- Publication type:
- Article
Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G.
- Published in:
- Thoracic Cancer, 2018, v. 9, n. 6, p. 750, doi. 10.1111/1759-7714.12644
- By:
- Publication type:
- Article
Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.
- Published in:
- Thoracic Cancer, 2018, v. 9, n. 1, p. 175, doi. 10.1111/1759-7714.12543
- By:
- Publication type:
- Article
Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M.
- Published in:
- Thoracic Cancer, 2018, v. 9, n. 1, p. 171, doi. 10.1111/1759-7714.12538
- By:
- Publication type:
- Article
Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.
- Published in:
- Thoracic Cancer, 2018, v. 9, n. 1, p. 193, doi. 10.1111/1759-7714.12557
- By:
- Publication type:
- Article
Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient.
- Published in:
- Thoracic Cancer, 2017, v. 8, n. 6, p. 706, doi. 10.1111/1759-7714.12494
- By:
- Publication type:
- Article
Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 3, p. 497, doi. 10.1007/s00280-014-2527-4
- By:
- Publication type:
- Article
Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.
- Published in:
- Cancer Management & Research, 2010, v. 2, p. 191
- By:
- Publication type:
- Article